Pediatric Myopia

Corneal cross-linking and the potential of robotics are the topics of the best performing cover stories so far in 2021.

Findings from a recent study indicated that home confinement during the COVID-19 pandemic appeared to be associated with an increase in myopia prevalence in younger school-aged children.

The thought that progressive myopia is a “disease” that deserves treatment is itself controversial. To add to the controversy, there is much debate concerning what constitutes appropriate treatment.

Patients with high myopia can be at risk for ocular pathology, so managing, slowing and treating myopia in pediatric patients with drugs, multifocal contact lenses and refractive surgery are necessary.

I do not believe that the potential benefit of reducing the progression of myopia in children outweighs the risks, which include microbial keratitis.

In this special episode, I sit down with this week’s co-host, my wife Yasmin P. Mali, MD, to discuss my top 5 predictions in ophthalmology in the new year. Stay tuned for a special announcement at the end of the show.

Bausch Health has licensed Eyenovia to develop and commercialize an investigational formulation of atropine delivered by Optejet dispenser, according to a press release.

Ella Faktorovich, MD, founder of Pacific Vision Institute in San Francisco, discusses a new phenomenon in the peer-review literature called “quarantine myopia” in children.

The distance at which a child views content on a mobile phone may have an effect on their risk for developing myopia over time, according to a speaker at the virtual Association for Research in Vision and Ophthalmology meeting.